Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation APTCF


Primary Symbol: V.APC.H

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation > Boom! Re-Rate On!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(27)
•••
Comment by Goldnboy1on Apr 11, 2021 11:04pm
139 Views
Post# 32975551

RE:RE:Boom! Re-Rate On!

RE:RE:Boom! Re-Rate On!Still time to average down a bit by the sounds of it! 

Very large group of shareholders with no interest in selling anytime soon! Float is extremely tiny and interest in the company rapidly changing for the better!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities